Prometheus Biosciences, Inc. (RXDX) Stock Analysis
DELISTED 2023
What happened to Prometheus Biosciences, Inc. (RXDX) stock?
Prometheus Biosciences, Inc. (RXDX) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- June 2023
- Last recorded price (historical):
- $199.92 (last quote on record before the June 2023 delisting; historical, not a current quote)
Market cap $9.56B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Prometheus Biosciences, Inc. (RXDX). Prometheus Biosciences, Inc. is a biopharmaceutical company specializing in innovative therapeutics and diagnostic products for inflammatory bowel diseases (IBD) and other immune-mediated conditions.
Last analyzed: Jun 13, 2026Prometheus Biosciences, Inc. (RXDX) Healthcare & Pipeline Overview
More about this archive record
Can I still buy RXDX shares?
No. RXDX stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for RXDX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RXDX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Prometheus Biosciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.